SUGAmmadex用于急诊科神经肌肉阻滞逆转的多中心回顾性队列研究:SUGARED研究——代表EMPHARM-NET研究者
这项多中心回顾性观察队列研究纳入11家美国急诊科、年龄≥18岁、使用罗库溴铵插管后接受舒更葡糖、主要诊断为创伤性脑损伤或自发性脑出血的患者,筛选时间为2015年12月15日至2024年6月30日。主要结局为舒更葡糖给药后30分钟内GCS升高≥1分的比例,362例中54%(n=196)出现该反应,GCS变化中位数3分(IQR 2-4,范围1-9)。有反应者中新增加镇痛药者30.6% vs 13.9%(差值16.8%,95%CI 8.4至25.1),新增加镇静药者33.7% vs 14.5%(差值19.2%,95%CI 10.7至27.7),神经外科手术率43.4% vs 33.7%(差值9.6%,95%CI -0.4至19.7,未达统计学显著)。作者结论认为急诊科使用舒更葡糖逆转罗库溴铵与GCS及镇痛镇静需求变化相关。
要点
- 急诊科创伤性脑损伤或自发性脑出血成人患者使用罗库溴铵插管后给予舒更葡糖,54%(196/362)在30分钟内GCS升高≥1分。
- 有反应者GCS变化中位数为3分(IQR 2-4,范围1-9)。
- 有反应者中新增加镇痛药的比例为30.6% vs 无反应者13.9%(差值16.8%,95%CI 8.4至25.1)。
- 有反应者中新增加镇静药的比例为33.7% vs 无反应者14.5%(差值19.2%,95%CI 10.7至27.7)。
- 有反应者神经外科手术率为43.4% vs 无反应者33.7%(差值9.6%,95%CI -0.4至19.7,未达统计学显著)。
适用人群与场景
- 年龄≥18岁、使用罗库溴铵插管后接受舒更葡糖、主要诊断为创伤性脑损伤或自发性脑出血的急诊科成人患者,筛选时间为2015年12月15日至2024年6月30日。
诊断标准与关键阈值
- 阳性神经反应定义为舒更葡糖给药后30分钟内GCS升高≥1分。
研究设计与关键结果
- 研究类型为多中心、回顾性、观察性队列研究,纳入11家美国急诊科,主要结局分析纳入362例患者。
- 舒更葡糖给药后30分钟内GCS升高≥1分者占54%(n=196),GCS变化中位数3分(IQR 2-4,范围1-9)。
- 有反应者中新增加镇痛药者30.6% vs 无反应者13.9%,差值16.8%(95%CI 8.4至25.1)。
- 有反应者中新增加镇静药者33.7% vs 无反应者14.5%,差值19.2%(95%CI 10.7至27.7)。
- 有反应者神经外科手术率43.4% vs 无反应者33.7%,差值9.6%(95%CI -0.4至19.7),未达统计学显著。
证据类型、等级与局限
- 证据类型为多中心回顾性观察性队列研究;原文未报告证据等级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,急诊科使用舒更葡糖逆转罗库溴铵与GCS及镇痛镇静需求变化相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: The objective of this study was to describe the proportion of emergency department (ED) patients with traumatic brain injury (TBI) or spontaneous intracranial hemorrhage (sICH) who demonstrated a positive neurologic response to sugammadex-mediated reversal of rocuronium, and to compare outcomes between responders and non-responders.
METHODS: This was a multicenter, retrospective, observational cohort study of 11 US Emergency Departments. Adult patients, aged ≥18 years, who were intubated using rocuronium and subsequently received sugammadex and had a primary diagnosis of TBI or sICH between December 15, 2015, to June 30, 2024 were screened for inclusion. The primary outcome of this study was the proportion of patients who had a positive response (defined as an increase in GCS of ≥1 point) within 30 min of sugammadex administration. The secondary outcomes included change in analgosedation requirements during the first 30 min post-sugammadex administration, and the rate of neurosurgical procedures.
RESULTS: The primary outcome analysis included 362 patients. An increase in GCS within 30 min post-sugammadex administration occurred in 54% (n = 196), with a median GCS change of 3 (IQR: 2-4, range 1-9). A positive response was associated with the addition of a new analgesic agent (30.6% 13.9%, difference = 16.8%, 95% confidence interval 8.4 to 25.1), sedation agent (33.7% vs. 14.5%, difference = 19.2%, 95% confidence interval 10.7 to 27.7), and a non-significant increase in neurosurgical procedures (43.4 vs. 33.7%, difference = 9.6%, 95% confidence interval -0.4 to 19.7).
CONCLUSION: Sugammadex administration to reverse rocuronium in the ED was associated with a significant change in GCS and analgosedation requirements.
参考来源
- Lawson C, Rech MA, Sun J, et al. A multi-center retrospective cohort study of SUGAmmadex for neuromuscular blockade reversal in the emergency department: SUGARED study - on behalf of EMPHARM-NET Investigators. Am J Emerg Med. 2026. PMID: 42349235. doi:10.1016/j.ajem.2026.06.021
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。